Restriction or avoidance
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Severe renal impairment contraindicates the fixed bismuth/metronidazole/tetracycline product. Limits and monitoring Confirm the combination and renal status before prescribing an H. pylori regimen. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 4, posted Jul 01, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Bortezomib does not require an initial renal reduction. On dialysis days, administer it after the dialysis procedure. Limits and monitoring Use the regimen and administration route appropriate to the indication. Follow toxicity separately. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 36, posted Sep 01, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding At CrCl 15-30 mL/min, parent bosentan concentrations changed little, although plasma levels of its metabolites were approximately doubled. Limits and monitoring The finding alone does not establish a dialysis supplement. Review the label's liver monitoring requirements. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 36, posted Jan 23, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Insufficient evidence
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding The disposition of quick-release bromocriptine in renal impairment has not been studied. Limits and monitoring This product-specific evidence gap supplies no renal dose or dialysis schedule. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 7, posted Jan 14, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure GFR/eGFR in mL/min as reported by the source Renal action or finding At GFR below 90 mL/min, consider a lower bupropion hydrobromide dose, a less frequent schedule, or both. Limits and monitoring Verify the ER salt and strength. Hydrobromide and hydrochloride tablet strengths are different. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 27, posted Mar 05, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding At CrCl 30 to below 90 mL/min no renal adjustment is required for the long-acting injection combination. With severe impairment or ESRD, increase monitoring for adverse effects. Limits and monitoring Verify the long-acting injectable regimen and the instructions for missed doses. Review 2 product or source cautions
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 16, posted Dec 05, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding At CrCl 15 to below 90 mL/min the oral cabotegravir dose does not require renal adjustment. Limits and monitoring Check interacting medicines and any companion rilpivirine instructions. Injection schedules are separate. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 8, posted Apr 18, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Mild or moderate renal impairment does not require a cabozantinib dose change. Experience in severe impairment is limited. Limits and monitoring Verify the product and indication. Cabometyx tablets and Cometriq capsules must not be substituted for one another. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 18, posted Nov 17, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Mild or moderate renal impairment does not require a cabozantinib dose change. Experience in severe impairment is limited. Limits and monitoring Verify the product and indication. Cabometyx tablets and Cometriq capsules must not be substituted for one another. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 16, posted Nov 17, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding For CrCl above 30 through 90 mL/min, the mild and moderate groups do not require a renal reduction. The severe evidence-gap statement includes CrCl 30, which also appears in the printed moderate range. Limits and monitoring Clarify the exact boundary at 30 mL/min before using the fixed combination. Check volume and electrolytes. Review 1 product or source caution
The renal categories overlap at exactly 30 mL/min in the cited wording. Resolve this boundary before use.
DailyMed SPL version 4, posted Dec 23, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Carvedilol concentrations can be higher in moderate or severe renal impairment. Hemodialysis is unlikely to remove a substantial amount of bound drug. Limits and monitoring The cited exposure findings concern immediate-release carvedilol. Titrate to the indication and hemodynamic response. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 3, posted Aug 03, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Insufficient evidence
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding No renal impairment trials were conducted with Coreg CR. The cited higher concentrations were measured with immediate-release carvedilol. Limits and monitoring The immediate-release findings do not establish a quantitative ER dose change. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 3, posted Apr 28, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Return to top Find another drug
